| Literature DB >> 36231609 |
Dejan Reljic1,2, Annalena Eichhorn1, Hans J Herrmann1,2, Markus F Neurath2,3, Yurdagül Zopf1,2.
Abstract
Initially, we aimed to investigate the impact of a one-year worksite low-volume, high-intensity interval training (LOW-HIIT) on cardiometabolic health in 114 sedentary office workers. Due to the COVID-19 pandemic outbreak, LOW-HIIT was discontinued after 6 months and participants were followed up for 6 months to analyze physical activity/exercise behavior and outcome changes during lockdown. Health examinations, including cardiopulmonary exercise testing and the assessment of cardiometabolic markers were performed baseline (T-1), after 6 months (T-2, termination of worksite LOW-HIIT) and 12 months (T-3, follow-up). Cycle ergometer LOW-HIIT (5 × 1 min at 85-95% HRmax) was performed 2×/week. For follow-up analyses, participants were classified into three groups: HIIT-group (continued home-based LOW-HIIT), EX-group (continued other home-based exercises), and NO-EX-group (discontinued LOW-HIIT/exercise). At T-2, VO2max (+1.5 mL/kg/min, p = 0.002), mean arterial blood pressure (MAB, -4 mmHg, p < 0.001), HbA1c (-0.2%, p = 0.005) and self-reported quality of life (QoL, +5 points, p < 0.001) were improved. At T-3, HIIT-group maintained VO2max and QoL and further improved MAB. EX-group maintained MAB and QoL but experienced a VO2max decrease. In NON-EX, VO2max, MAB and QoL deteriorated. We conclude that LOW-HIIT can be considered a promising option to improve cardiometabolic health in real-life conditions and to mitigate physical inactivity-related negative health impacts during lockdowns.Entities:
Keywords: cardiometabolic health; exercise; health promotion; lockdown; occupational health management; physical activity
Mesh:
Year: 2022 PMID: 36231609 PMCID: PMC9565952 DOI: 10.3390/ijerph191912308
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Study flow chart.
Mean values and standard deviations (SD) of participants’ (N = 71) cardiorespiratory fitness data pre- (T-1) and post-intervention (T-2).
| Variable | T-1 | T-2 |
|---|---|---|
| Relative VO2max (mL/kg/min) | 34.2 ± 8.6 | 35.6 ± 7.5 ** |
| Absolute VO2max (L/min) | 2.9 ± 0.8 | 3.0 ± 0.8 ** |
| Relative peak power output (W/kg) | 2.7 ± 0.7 | 3.0 ± 0.7 *** |
| Absolute peak power output (W) | 223 ± 59 | 247 ± 61 *** |
| Power output at VT (W) | 99 ± 41 | 141 ± 46 *** |
VO2max, maximum oxygen uptake; VT, ventilatory threshold. **, and *** indicate p < 0.01, and p < 0.001 vs. T-1 in paired t-tests.
Mean values and standard deviations (SD) of participants’ (N = 71) body composition and cardiometabolic data at baseline (T-1) and post-intervention (T-2).
| Variable | T-1 | T-2 |
|---|---|---|
| Body weight (kg) | 84.3 ± 18.5 | 83.8 ± 18.4 |
| Body mass index (kg/m2) | 26.9 ± 4.6 | 26.8 ± 4.8 |
| Waist circumference, (cm) | 89.3 ± 17.1 | 91.4 ± 13.4 |
| Body fat mass (%) | 30.0 ± 9.4 | 30.7 ± 8.9 |
| Fat free mass (kg) | 58.7 ± 12.2 | 58.0 ± 12.0 |
| Resting heart rate (b/min) | 89 ± 20 | 71 ± 10 *** |
| Systolic BP (mmHg) | 131 ± 14 | 129 ± 13 |
| Diastolic BP (mmHg) | 90 ± 10 | 85 ± 8 *** |
| MAB (mmHg) | 103 ± 11 | 99 ± 9 *** |
| Fasting glucose (mg/dL) | 102 ± 25 | 101 ± 13 |
| HbA1c (%) | 5.4 ± 0.6 | 5.2 ± 1.0 ** |
| Triglycerides (mg/dL) | 116 ± 54 | 109 ± 64 |
| Total cholesterol (mg/dL) | 222 ± 41 | 222 ± 38 |
| HDL (mg/dL) | 58 ± 14 | 59 ± 14 |
| LDL (mg/dL) | 145 ± 34 | 141 ± 30 |
BP, blood pressure; MAB, mean arterial blood pressure; HbA1c, glycosylated hemoglobin A1c; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol. **, and *** indicate p < 0.01, and p < 0.001 vs. T-1 in paired t-tests and Wilcoxon test (only HbA1c), respectively.
Mean values and standard deviations (SD) of participants’ (N = 71) self-reported outcomes at baseline (T-1) and post-intervention (T-2).
| Variable | T-1 | T-2 |
|---|---|---|
| EQ-5D-5L (index) | 0.96 ± 0.06 | 0.94 ± 0.09 |
| EQ (VAS) | 78 ± 12 | 83 ± 10 *** |
| Work Ability Index | 41 ± 4 | 42 ± 4 |
| PSQ-worries | 21 ± 18 | 18 ± 14 |
| PSQ-tension | 30 ± 21 | 27 ± 17 |
| PSQ-joy | 67 ± 22 | 70 ± 22 |
| PSQ-demands | 39 ± 21 | 36 ± 18 |
EQ, EuroQol Group questionnaire; VAS, visual analogue scale; PSQ, Perceived Stress Questionnaire. *** indicates p < 0.001 vs. T-1 in Wilcoxon test.
Mean values and standard deviations (SD) of participants’ (N = 57) age at follow-up (T-3), physical activity and nutritional intakes prior to the post-intervention (T-2) and follow-up examination (T-3).
| Variable | HIIT-Group (N = 19) | EX-Group (N = 12) | NO-EX-Group (N = 26) | |||
|---|---|---|---|---|---|---|
| T-2 | T-3 | T-2 | T-3 | T-2 | T-3 | |
| Age (yrs) | --- | 50 ± 9 | --- | 52 ± 8 | --- | 47 ± 12 |
| Light PA (hours/week) | 4.0 ± 2.0 | 2.9 ± 1.0 * | 3.6 ± 1.6 | 3.0 ± 1.2 | 4.4 ± 2.1 | 3.4 ± 1.9 *** |
| Moderate PA (hours/week) | 0.8 ± 0.8 | 0.3 ± 0.5 ** | 0.8 ± 0.7 | 0.2 ± 0.4 * | 1.2 ± 0.8 | 0.4 ± 0.5 *** |
| MET hours/week | 11.0 ± 5.5 | 6.1 ± 3.3 *** | 10.9 ± 4.2 | 6.2 ± 3.1 ** | 13.6 ± 6.6 | 8.2 ± 4.3 *** |
| Energy intake(kcal) | 2403 ± 858 | 2697 ± 1389 | 1946 ± 584 | 2051 ± 637 | 2174 ± 642 | 2062 ± 529 |
| CHO intake (g) | 246 ± 92 | 272 ± 137 | 209 ± 71 | 210 ± 75 | 219 ± 79 | 210 ± 57 |
| Fat intake (g) | 101 ± 43 | 110 ± 63 | 70 ± 29 + | 79 ± 31 + | 91 ± 28 | 83 ± 30 |
| Protein intake (g) | 96 ± 41 | 114 ± 62 | 77 ± 30 | 89 ± 38 | 87 ± 32 | 89 ± 29 |
PA, physical activity; MET, metabolic equivalent; CHO, carbohydrates. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 vs. T-2, and + indicates p < 0.05 vs. HIIT-group, respectively, in 2-way repeated measures ANOVAs.
Mean values and standard deviations (SD) of participants’ (N = 57) cardiorespiratory fitness data at post-intervention (T-2) and follow-up (T-3).
| Variable | HIIT-Group (N = 19) | EX-Group (N = 12) | NO-EX-Group (N = 26) | |||
|---|---|---|---|---|---|---|
| T-2 | T-3 | T-2 | T-3 | T-2 | T-3 | |
| Relative VO2max (mL/kg/min) | 35.0 ± 5.7 | 35.0 ± 6.1 | 36.7 ± 6.5 | 32.9 ± 7.6 *** | 37.5 ± 8.2 | 31.6 ± 8.2 *** |
| Absolute VO2max (L/min) | 3.0 ± 0.6 | 2.9 ± 0.6 | 2.7 ± 0.6 | 2.4 ± 0.7 *** | 3.1 ± 0.6 | 2.5 ± 0.9 *** |
| Relative peak power output (W/kg) | 2.9 ± 0.6 | 2.9 ± 0.5 | 3.2 ± 0.6 | 3.1 ± 0.6 | 3.0 ± 0.7 | 2.9 ± 0.7 |
| Absolute peak power output (W) | 253 ± 46 | 241 ± 40 | 243 ± 60 | 238 ± 62 | 251 ± 65 | 241 ± 60 |
| Power output at VT (W) | 137 ± 47 | 122 ± 30 | 154 ± 45 | 112 ± 47 *** | 146 ± 47 | 110 ± 37 *** |
VO2max, maximum oxygen uptake; VT, ventilatory threshold. *** indicates p < 0.001 vs. T-2 in 2-way repeated measures ANOVAs.
Mean values and standard deviations (SD) of participants’ (N = 57) body composition and cardiometabolic data at post-intervention (T-2) and follow-up (T-3).
| Variables | HIIT-Group (N = 19) | EX-Group (N = 12) | NO-EX-Group (N = 26) | |||
|---|---|---|---|---|---|---|
| T-2 | T-3 | T-2 | T-3 | T-2 | T-3 | |
| Body weight (kg) | 87.5 ± 18.8 | 86.3 ± 18.4 | 73.4 ± 13.3 | 75.4 ± 14.0 | 83.7 ± 20.2 | 83.4 ± 19.2 |
| Body mass index (kg/m2) | 27.8 ± 4.7 | 27.5 ± 5.1 | 24.9 ± 3.1 | 25.0 ± 3.2 | 25.9 ± 4.8 | 25.8 ± 4.6 |
| Waist circumference, (cm) | 96.8 ± 14.1 | 95.3 ± 12.9 | 87.2 ± 11.5 | 86.8 ± 10.1 | 89.8 ± 13.7 | 89.7 ± 13.5 |
| Body fat mass (%) | 29.9 ± 7.7 | 29.1 ± 7.9 | 27.9 ± 6.4 | 28.0 ± 6.6 | 29.6 ± 9.9 | 29.5 ± 9.1 |
| Fat free mass (kg) | 60.5 ± 10.8 | 60.4 ± 10.7 | 54.4 ± 11.4 | 54.4 ± 11.0 | 58.6 ± 13.2 | 58.3 ± 13.1 |
| Resting heart rate (b/min) | 73 ± 12 | 71 ± 9 | 69 ± 8 | 70 ± 12 | 72 ± 9 | 83 ± 10 *** |
| Systolic BP (mmHg) | 135 ± 12 | 126 ± 12 ** | 126 ± 15 | 123 ± 13 | 126 ± 12 | 127 ± 11 |
| Diastolic BP (mmHg) | 89 ± 8 | 84 ± 8 * | 85 ± 9 | 83 ± 7 | 84 ± 6 | 86 ± 7 |
| MAB (mmHg) | 102 ± 9 | 98 ± 8 * | 98 ± 11 | 97 ± 9 | 98 ± 7 | 101 ± 8 * |
| Fasting glucose (mg/dL) | 100 ± 10 | 101 ± 11 | 102 ± 19 | 108 ± 21 | 101 ± 13 | 105 ± 19 |
| HbA1c (%) | 5.4 ± 0.3 | 5.4 ± 0.3 | 5.5 ± 0.5 | 5.5 ± 0.4 | 5.3 ± 0.4 | 5.4 ± 0.5 |
| Triglycerides (mg/dL) | 120 ± 68 | 120 ± 91 | 85 ± 32 | 94 ± 44 | 108 ± 68 | 119 ± 71 |
| Total cholesterol (mg/dL) | 226 ± 36 | 228 ± 39 | 215 ± 28 | 221 ± 37 | 222 ± 45 | 228 ± 45 |
| HDL (mg/dL) | 54 ± 11 | 57 ± 11 | 62 ± 15 | 62 ± 17 | 62 ± 18 | 62 ± 16 |
| LDL (mg/dL) | 147 ± 29 | 149 ± 33 | 134 ± 30 | 140 ± 34 | 139 ± 33 | 146 ± 34 |
BP, blood pressure; MAB, mean arterial blood pressure; HbA1c, glycosylated hemoglobin A1c; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001 vs. T-2 in 2-way repeated measures ANOVAs.
Mean values and standard deviations (SD) of participants’ (N = 57) self-reported outcomes at post-intervention (T-2) and follow-up (T-3).
| Variable | HIIT-Group (N = 19) | EX-Group (N = 12) | NO-EX-Group (N = 26) | |||
|---|---|---|---|---|---|---|
| T-2 | T-3 | T-2 | T-3 | T-2 | T-3 | |
| EQ-5D-5L (index) | 0.92 ± 0.07 | 0.93 ± 0.07 | 0.96 ± 0.06 | 0.94 ± 0.08 | 0.95 ± 0.04 | 0.94 ± 0.06 |
| EQ (VAS) | 81 ± 10 | 80 ± 13 | 86 ± 8 | 85 ± 8 | 85 ± 7 | 80 ± 11 * |
| Work Ability Index | 42 ± 4 | 42 ± 3 | 43 ± 4 | 43 ± 3 | 42 ± 4 | 43 ± 3 |
| PSQ-worries | 20 ± 15 | 21 ± 16 | 23 ± 16 | 19 ± 16 | 14 ± 18 | 16 ± 13 |
| PSQ-tension | 32 ± 22 | 35 ± 22 | 27 ± 11 | 34 ± 22 | 26 ± 12 | 30 ± 22 |
| PSQ-joy | 64 ± 28 | 60 ± 27 | 75 ± 17 | 71 ± 23 | 73 ± 20 | 70 ± 17 |
| PSQ-demands | 45 ± 19 | 43 ± 20 | 37 ± 16 | 42 ± 23 | 36 ± 18 | 34 ± 22 |
| PSQ-total | 34 ± 19 | 35 ± 18 | 27 ± 13 | 32 ± 21 | 27 ± 11 | 27 ± 15 |
EQ, EuroQol Group Questionnaire; VAS, visual analogue scale; PSQ, Perceived Stress Questionnaire. * indicates p < 0.05, vs. T-2 in Friedman two-way analyses by ranks.